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Introduction: Prosthetic joint infections are severe complications of joint implants. Further complications arise
when polymicrobial and/or multidrug-resistant microorganisms are involved. Currently, there are limited data on
the management of these infections and on the tolerability of long-term treatment with daptomycin, ceftazidime
and colistin.
Case presentation: A 55-year-old Caucasian woman who had a right hip prosthesis removed 1 year prior because
of infection was admitted for prosthesis reimplantation. On admission at our hospital, anamnesis regarding etiology
and management of prosthesis infection was not available. On clinical, laboratory findings and imaging studies
infection was not suspected. A hip prosthesis was reimplanted. At surgery, histopathological and microbiological
investigations were not taken. Three weeks after reimplantation, surgical site infection due to Enterobacter cloacae
was diagnosed and oral ciprofloxacin was prescribed. Four days later, a periprosthesis fluid collection was evidenced
and a percutaneous needle aspirate grew Staphylococcus epidermidis and S. haemolyticus. Enterobacter genome was
also detected from the same sample. Teicoplanin and meropenem were added to ciprofloxacin without clinical
improvement. Moreover, acetabular cup dislocation was documented. She underwent prosthesis explantation,
debridement, and positioning of an antimicrobial mixed spacer. From the intraoperatory cultures S. epidermidis and
Acinetobacter baumannii were grown. Daptomycin, ceftazidime, colistin and rifampin were administered. Four days
later, rifampin was stopped due to a suspected liver toxicity. While undergoing therapy she presented recurrent
episodes of wound dehiscence and on the 22nd week of treatment a further surgical debridement was performed,
upon which the spacer was removed. At this time, intraoperative cultures resulted negative. Three months later,
after a total of 8 months, antimicrobials were interrupted. Subsequently, a femoral transcondylar traction was
positioned, and 3 weeks later a new prosthesis was reimplanted. At over 1 year after reimplantation she is well.
Conclusions: Our findings suggest that microbiologic investigations are mandatory even when prosthetic joint
infection is not suspected. Molecular methods for identification of microorganisms can be used in addition to
conventional cultures especially when patients are under antibiotic treatment. Daptomycin, ceftazidime and colistin
can be administered for several months without side effects. Guidelines specifically addressing the diagnosis and
the management of polymicrobial, multidrug-resistant prosthetic joint infections need to be developed.* Correspondence: mariabruna.pasticci@unipg.it
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Figure 1 Acinetobacter baumannii: E-test, interaction between
colistin and rifampin. Fractional inhibitory concentration=1.37 [13].
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Prosthetic joint infection (PJI) is one of the most severe
complications of joint replacement [1]. Although this is
a rare event [1], the overall burden is high as a conse-
quence of an increased number of implanted prosthesis
in the aging population, an increased number of patients
with risk factors for infection and improved methods to
detect these infections. PJIs are associated with high
morbidity, a need of complex treatment, prolonged
hospitalization and substantial healthcare costs. Moreover,
PJIs can lead to impaired functioning or even permanent
disability [1,2]. Further complications arise when poly-
microbial, multi-drug-resistant (MDR) [3,4] or difficult
to treat microorganisms are involved [5-10].
Here, a complicated case of PJ reinfection is reported.
Case presentation
A 55-year-old Caucasian woman was admitted for a right
hip prosthesis reimplantation. The first arthroplasty was
performed 3 years earlier due to hip osteoarthritis. How-
ever, after 2 years her prosthesis had been explanted and a
spacer positioned due to infection. After 1 month the spa-
cer had also been removed. No further data on microbio-
logical results and medical treatment were available at the
time of her admission at our hospital. On admission, she
was complaining of pain and was not taking antibiotic
therapy. Her erythrocyte sedimentation rate (ESR) was
35mm 1°hour, her white blood cell count and differential
were normal, C-reactive protein (C-RP) was not available
and a leukocyte scan resulted normal. She underwent hip
reimplantation. At surgery, histopathological and micro-
biological investigations were not taken. After arthro-
plasty, she was discharged. Two weeks later she was seen
as an out-patient complaining of hip pain, motion impair-
ment and dehiscence of the wound. Enterobacter cloacae
was grown from the wound exudate. The isolate was an
extended spectrum β-lactamase producer, resistant to gen-
tamicin, and susceptible to ciprofloxacin, imipenem, and
colistin, according to Clinical and Laboratory Standards
Institute (CLSI) breakpoints [11]. She was started on a
treatment with oral ciprofloxacin 500mg twice per day.
Four days later, ultrasound evidenced periprosthesis fluid
collection. Staphylococcus epidermidis and S. haemolyticus
were cultured from the needle aspiration. Both coagulase-
negative staphylococci (CoNS) isolates resulted oxacillin
and ciprofloxacin resistant, teicoplanin susceptible [11].
The same sample was also examined with the commercial
real-time polymerase chain reaction-based system, Septi-
Fast (Roche Molecular Diagnostics, Mannheim, Germany)
which detected E. cloacae/aerogenes and CoNS genomes.
At this point, the patient was readmitted. Teicoplanin
intravenous 400mg per day and meropenem intravenous
2g three times per day (patient’s weight was 68kg) were
added to ciprofloxacin without clinical improvement.After 2 weeks, E. cloacae with the same susceptibility
pattern of the previous isolate and Acinetobacter bau-
mannii were grown from the aspirated synovial fluid of
her hip. A. baumannii isolate resistant to aztreonam, ce-
fepime, cefotaxime, ciprofloxacin, imipenem, fosfomy-
cin, gentamicin, and trimethoprim/sulfamethoxazole,
but susceptible to ceftazidime and colistin [11] was ob-
tained. Tigecycline minimal inhibitory concentration
was 1.5mg/L, however, no breakpoints were available for
this antimicrobial agent against A. baumannii, according
to CLSI [11]. At this point, a standard radiograph evi-
denced acetabular cup dislocation, therefore her prosthesis
was removed. During surgery, extensive debridement was
performed and a spacer with vancomycin and gentamicin
was inserted. From the periprosthesis tissue samples, and
her prosthesis, S. epidermidis and A. baumannii were
identified while from the synovial fluid only S. epidermidis
was isolated. Susceptibility patterns of A. baumannii iso-
lates did not differ. The susceptibility pattern of the two
latter S. epidermidis isolates was different from that of the
previous one in respect to erythromycin, clindamycin, and
trimethoprim/sulfamethoxazole. Ceftazidime was added to
the pre-existing therapy. When in vitro antimicrobial sus-
ceptibility [11] with synergism results (Figure 1) [12,13]
were made available, therapy was modified as follows:
daptomycin intravenous 500mg per day, ceftazidime
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3 million units three times per day, and rifampin 600mg
daily administered orally. Four days later, rifampin was
stopped due to a suspected liver toxicity. Overall, her
condition improved despite recurrent episodes of wound
dehiscence and purulence. After almost 12 weeks of anti-
microbial treatment, she was accepted into a protected
residence where she continued to undergo treatment
of intravenous antimicrobial therapy with daptomycin
500mg per day, ceftazidime 2g three times per day, and
colistin 3 million units three times per day. One month
later, a computed tomography (CT) scan of her hip
showed liquid around the spacer and femur inflammatory
reaction (Figure 2). Two weeks later, another dehiscence
of the wound manifested. She was readmitted for an ulter-
ior debridement and this time the spacer was also re-
moved. Prior to surgery antimicrobial therapy was not
interrupted. Intraoperative microbiological investigations
resulted negative including the molecular SeptiFast test.
After surgery she returned to the protected residence and
continued the same antimicrobial therapy. Three weeks
later, colistin was reduced from 3 to 2 million units intra-
venous per day every 8 hours. After a total of 8 months,
all antimicrobials were stopped. During the entire period
antimicrobial therapy was administered, she was clinically
monitored and, every 10 days, ESR, C-RP, blood count,
creatine phosphokinase, liver and kidney function tests
and electrolytes were obtained. No side effects were ob-
served during treatment. When antimicrobials were dis-
continued, a further CT of her hip evidenced dislocation
of her femur and inflammatory tissue surrounding her
femur and the acetabular cavity. During the following 3-
month period, she did not manifest clinical evidence of in-
fection, and her ESR and C-RP were normal; then she was
readmitted to another hospital to be reimplanted. A fem-
oral transcondylar traction was first positioned for over 3
weeks in order to extend her muscles, thereafter a third
prosthesis was implanted. At surgery, there was no evi-
dence of purulence; however, there was necrotic tissue
which underwent debridement. After several samples wereFigure 2 Computed tomography. a) Coronal and b) axial images showingcollected for microbiologic investigations, she was admin-
istered daptomycin intravenous 500mg per day, ceftazi-
dime intravenous 6g per day, and colistin intravenous 2
million units three times per day until microbiological re-
sults, including the SeptiFast test, were reported negative.
For more than a year since her third prosthesis was reim-
planted, she has been asymptomatic and has regained
motility.
Discussion
There are several guidelines on the diagnosis and the
management of PJIs; however, polymicrobial, MDR and
difficult to treat PJIs [5,6] have not been thoroughly
addressed.
This article reports a polymicrobial, MDR prosthesis
reinfection successfully treated with a two-stage long
interval reimplant and prolonged antimicrobial therapy.
In our case, E. cloacae, A. baumannii and CoNS were
the more probable etiologies of the infection. In fact, all
the microorganisms, even in different combinations and
at different times, were identified from multiple intraop-
erative tissues, prosthesis, and periprosthesis and syn-
ovial fluid aspirates [14-16]. It is impossible to state if
any of the isolated microorganisms had already been
present in a nonreplicating phase in the involved articula-
tion at the time of the first reimplantation at our hospital.
Nonperforming intraoperative histopathological and micro-
biological examinations can lead to missed cases of pros-
thesis infections [2,5,14-16]. Improper sample collection,
small colony variants [7,8], antimicrobial therapy before or
during surgery and a lack of sonication [17-19] can also
hinder diagnosis and etiology of PJIs [1,2,5,13-20]. Small
colony variants as well can lead to problems in micro-
organism identification and antimicrobial susceptibility re-
sults [7,8]. However, in our case, it was not possible to
verify if the observed differences for CoNS in respect to
susceptibility and identification results were due to small
colony variants.
The SeptiFast test has been commercialized for the
diagnosis of sepsis from peripheral blood samples andfluid around the spacer, femoral inflammation, and spacer dislocation.
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has been suggested to have a potentiality in detecting
pathogens also from specimens other than blood, like
sonicated fluids from removed prosthesis and synovial
fluids [19,22]. Its sensitivity was better than that of cul-
ture in patients under antibiotic treatment [22]. In our
case Enterobacter cloacae/aerogenes and CoNS genomes
were detected with the SeptiFast test in the aspirated
periprosthetic fluid, and contemporary cultures grew S.
epidermidis and S. haemolyticus. At that time, the pa-
tient had been diagnosed surgical site infection and was
on oral ciprofloxacin, active in vitro against E. cloacae
but not against CoNS. The clinical significance of deoxy-
ribonucleic acid (DNA) in the blood of septic patients in
the absence of microorganism growth is still not opti-
mally defined [21] and there is limited data on other bio-
logical samples. However, in our case, the fact that, 8
days later, E. cloacae was isolated from the aspirated syn-
ovial fluid points to the clinical relevance of the molecu-
lar results. The absence of bacterial DNA and viable
microorganisms in intraoperative samples at the time
the prosthesis was implanted for the third time was used
to further support the absence of residual infection. Cul-
ture has the ability to identify microorganisms not in-
cluded in the SeptiFast panel and to allow susceptibility
testing. Thus, it is reasonable to use a molecular test in
adjunct to culture in patients with PJIs under antibiotic
therapy.
Regarding the most effective surgical strategy for PJIs
and the best time of prosthesis reimplantation, the deci-
sion depends on the operating orthopedic surgeon, med-
ical specialists, and the patient [16]. Concerning the use
of spacers, some researchers recommend avoiding ce-
ment spacers when infections are due to MDR or diffi-
cult to treat microorganisms such as quinolone-resistant
and rifampin-resistant staphylococci, quinolone-resistant
Gram-negative microorganisms, small colony variants,
or fungi [5-8,16,20]. However, other researchers suggest
avoiding external fixations in the presence of bone infec-
tion, but instead perform debridement repeatedly and
change spacers as necessary. Furthermore, antimicrobial
impregnated spacers, either premixed or prepared by the
surgeons, can cause systemic toxicity [16]. The optimal
timing for prosthesis reimplantation is another issue
lacking controlled randomized studies to support a spe-
cific recommendation [16]. In our patient, initially, a ce-
ment spacer was positioned, then, it was removed and
for a 3-month interval our patient was left without a
spacer, continuing intravenous antimicrobial therapy.
Then, after a long interval without antimicrobials, clin-
ical signs of infection and normal ESR and C-RP results,
she was readmitted for reimplantation. Overall, in our
patient there was a delay of 1 year between prosthesis
explant and reimplantation, due to the fact that: 1)clinically, the infection was not fully controlled until the
spacer was left in place, 2) the patient had undergone
hip prosthesis surgery twice and was at high risk for fur-
ther infective complications.
In our case, recovery from infection was obtained with
surgical therapy and a combination of antimicrobial treat-
ment with daptomycin, ceftazidime, and colistin that were
finally efficacious and well tolerated. It is possible that ini-
tial antibiotic therapy with teicoplanin, ceftazidime and
ciprofloxacin was not completely effective due to biofilm
infection, suboptimal dosing of teicoplanin, and resulting
CoNS ciprofloxacin resistance.
Conclusions
Our findings suggest that microbiologic investigations
are mandatory even when PJI is not suspected on clinical
and laboratory findings and imaging studies. Molecular
methods for identification of microorganisms can be used
in addition to conventional cultures in patients with PJIs
especially when they are under antibiotic treatment. Dap-
tomycin, ceftazidime and colistin can be administered for
several months without side effects. Guidelines specifically
addressing the diagnosis and the management of polymi-
crobial, MDR PJIs need to be developed.
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